Dear Colleagues,

Below, please find some informal notes from the meeting that took place last Monday. Please let me know in case you would have comments.

With best regards,

Second meeting of the Working Group on a potential new public-private partnership for health R&I under Horizon Europe of 8 October 2018.

Participants:
- Representatives from industry: (by phone), (by phone) (MedTech Europe);
- Commission representatives: (CNECT.H); (GROW.D); (RDT.E); (SANTE.B), (SANTE.C);
- IMI2 JU Programme Office representative;
- Italian Istituto Sanità Superiore (during the first 30 minutes of the meeting).

Main points discussed:
- The “To-Reach” ([www.to-reach.eu](http://www.to-reach.eu)) project and its future developments, as presentation by .
- Overall objectives of a future public-private partnership:
  - The overall objective would be to establish a “neutral” platform for R&I in areas of clear public health need, enabling integrated healthcare, bringing together the necessary industries, and bringing together the necessary private and public stakeholders, in the precompetitive space.
  - Industry representatives stressed that the objective is to break silos both between industries and between private and public sectors. The initiative would be unique for enabling this to happen. Also, the definition of “precompetitive space” might vary between industries.
  - There was agreement that “integrated healthcare” would not be limited to “integrated products and services”, but would instead cover the whole continuum from health promotion, disease prevention, interception, diagnosis, to treatment and management. Such partnership could go beyond medical intervention, by including home and assisted living.
Such platform would generate innovations addressing needs and challenges of the healthcare systems, for the benefit of patients and citizens, and for healthcare industry to bring to markets. Such platform would provide evidences on the value of these innovations for patients, healthcare outcomes and healthcare systems, notably via pilots and demonstrators.

It was recognised that digitalisation would be an important enabler, and that consequently, appropriate digital companies need to contribute to such partnership.

The potential role in the partnership of public institutions other than EU (e.g. national/local healthcare authorities) was discussed, notably at the level of idea generation, to ensure that the needs and challenges of the healthcare systems are being addressed. Further discussions will need to take place on this issue and how this could be implemented.

It was also recognised that a broader stakeholder consultation would be needed to feed in these discussions and quickly agree on common aims.

Expected impacts:

- From the EC point of view, impacts could be expected on: Delivering innovations, methods, etc., combining various technologies; Providing evidences and solutions conducive to the regulatory environment; Better understanding the economic impact of integrated healthcare and building new business models; Developing data solutions (e.g. in the field of real world data) for R&I needs and interoperable with healthcare systems; Delivering standards and establishing interconnectivity/interoperability between industrial sectors, and with public operators; Bringing evidences for more efficient healthcare systems and contributing to improving their sustainability.

- The industry representatives questioned how much some of these impacts identified by the EC should not instead be considered as expected outcomes.

- From the industry point of view, the initiative should have impacts on the citizens/patients, healthcare systems, healthcare professionals and the industries themselves, which were briefly listed in the meeting.

- What should be considered as outputs versus impacts will need to be further reflected upon.

Expected areas:

- From the EC point of view, examples of areas could cover themes such as chronic diseases and co-morbidities, diabetes in the home and hospital environment, or brain disorders. The industry representatives also mentioned other areas such as cancer and infectious diseases.

- The EC expressed the view that such partnership should remain focused, potentially around only few areas. The industry however pointed out that the focus should not be too limiting. The actual areas should indeed enable effective commitment from companies, in particular in view of mobilising in-kind contributions. It was however agreed that industry would identify concrete examples with expected impacts and deliverables, and show how relevant they are for the full/broader sector.

Action points:

- EC to share with industry the slides about the “To-Reach” project (document attached to this e-mail)
- EC to share with industry the draft Strategic R&I Agenda from the “To-Reach” project (provided that the consortium agrees with sharing this document)
- Industry to share with EC a two-pager summarising the industries' position on the objectives, expected impacts, and examples of areas with concrete examples of impacts expected and deliverables, as well as demonstrating how relevant they are for the full/broader sector
- Industry and EC to identify stakeholders that should be involved, and a path for consulting these stakeholders

Issues to be addressed at next meeting, on 18 October 2018:

- Governance issues (including the role of member states, of regulators, how to bring in other funders)
- When and how to expect the commitment from industry
- Funding models and contributions (including eligibility for funding, contributions expected, in-kind incurred outside Europe and impact of Brexit)
- Discussion on the 2-pager proposed by industry
- Types of stakeholders to be involved in the partnership, and discussion on how and when to reach out to them
- EC to answer to specific questions from industry in interpreting the selection criteria for new European Partnerships as proposed in the Horizon Europe EC proposal